#1 Clinical Trials Search in Europe

Buclizine Hydrochloride

This article examines several clinical trials investigating the use of Buclizine Hydrochloride, often in combination with other drugs like paracetamol and codeine phosphate, for various medical conditions. The trials focus on pain management in conditions such as chronic neuropathic pain, back pain, and lupus nephritis, as well as its potential use in other disorders like propionic acidemia and B-cell lymphoma. These studies aim to evaluate the efficacy, safety, and optimal dosing of Buclizine Hydrochloride-containing medications in different patient populations.

Table of Contents

What is Buclizine Hydrochloride?

Buclizine Hydrochloride is a medication that belongs to a class of drugs known as antihistamines. It is also sometimes referred to as Buclizine dihydrochloride.[1] Antihistamines work by blocking the effects of histamine, a substance in the body that can cause allergic symptoms.

What is Buclizine Hydrochloride Used For?

Buclizine Hydrochloride is primarily used as an antiemetic, which means it helps prevent and treat nausea and vomiting. It may be prescribed for various conditions, including:

  • Motion sickness
  • Vertigo (a sensation of spinning or dizziness)
  • Nausea and vomiting associated with various medical conditions

Combination with Other Medications

In the clinical trials data, Buclizine Hydrochloride is often mentioned in combination with two other active substances: Paracetamol (also known as Acetaminophen) and Codeine Phosphate.[2] This combination is used as an analgesic, which means it helps relieve pain. The combination of these three substances may provide more comprehensive relief for patients experiencing both pain and nausea.

How is Buclizine Hydrochloride Administered?

Based on the information from the clinical trials, Buclizine Hydrochloride in combination with Paracetamol and Codeine Phosphate is typically administered orally.[3] However, some trials mention both oral and intravenous (IV) routes of administration.[4] The specific route and dosage would be determined by your healthcare provider based on your individual needs and medical condition.

Potential Side Effects

As with any medication, Buclizine Hydrochloride may cause side effects. Common side effects of antihistamines like Buclizine Hydrochloride can include:

  • Drowsiness
  • Dry mouth
  • Blurred vision
  • Constipation

It’s important to note that when Buclizine Hydrochloride is combined with Paracetamol and Codeine Phosphate, additional side effects may occur. Always consult with your healthcare provider about potential side effects.

Precautions and Considerations

When taking Buclizine Hydrochloride, especially in combination with other medications, there are several precautions to keep in mind:

  • Inform your doctor of any allergies you have, particularly to antihistamines.
  • Discuss all medications you’re currently taking, including over-the-counter drugs and supplements.
  • Be cautious when driving or operating machinery, as this medication may cause drowsiness.
  • Avoid alcohol consumption while taking this medication.
  • If you’re pregnant, planning to become pregnant, or breastfeeding, consult your doctor before using this medication.

Ongoing Research

While the clinical trials data provided doesn’t specifically focus on Buclizine Hydrochloride alone, it’s worth noting that this medication is being used in various studies as part of a combination therapy. These studies are investigating its use in treating different types of pain, including chronic back pain, neuropathic pain, and pain associated with certain cancers.[3] However, it’s important to remember that these are ongoing clinical trials, and the results are not yet conclusive.

Always consult with your healthcare provider for the most up-to-date and personalized information regarding Buclizine Hydrochloride and its potential uses in your specific medical situation.

Trial Focus Key Objectives Patient Population Primary Endpoints
Chronic Neuropathic Pain Evaluate efficacy and safety of AP707 (containing Buclizine Hydrochloride) Patients with chronic pain due to traumatic or post-operative peripheral neuropathy Change in pain level on Numeric Rating Scale at Week 14
Chronic Back Pain Assess efficacy and tolerability of AP707 Patients with chronic back pain Change in pain level on Numeric Rating Scale at Week 14
Lupus Nephritis Evaluate efficacy and safety of obinutuzumab (with Buclizine Hydrochloride as rescue medication) Patients with Class III or IV Lupus Nephritis Proportion of patients achieving complete renal response at Week 76
Propionic Acidemia Assess safety and efficacy of mRNA-3927 (with Buclizine Hydrochloride as analgesic) Patients with Propionic Acidemia Incidence and severity of adverse events; Annualized frequency of metabolic decompensation events
B-cell Lymphoma Determine maximum tolerated dose and recommended phase 2 dose of epcoritamab (with Buclizine Hydrochloride as analgesic) Patients with relapsed, progressive or refractory B-cell lymphoma Dose-limiting toxicity; Overall response rate

FAQ

  • What is Buclizine Hydrochloride? Buclizine Hydrochloride is a medication often used in combination with other drugs like paracetamol and codeine phosphate. It is being studied for its potential in managing various types of pain and other medical conditions.
  • What types of conditions are being studied in these clinical trials? The clinical trials are investigating the use of Buclizine Hydrochloride-containing medications for conditions such as chronic neuropathic pain, chronic back pain, lupus nephritis, propionic acidemia, and B-cell lymphoma.
  • How is the effectiveness of the medication being measured in these trials? The effectiveness is being measured through various methods, including changes in pain levels using numeric rating scales, improvements in quality of life, changes in disease-specific markers, and overall response rates to treatment.
  • Are there any safety concerns being evaluated in these trials? Yes, all the trials are assessing the safety and tolerability of the medication. This includes monitoring for adverse events, changes in laboratory values, and any other potential side effects.
  • How long do these clinical trials typically last? The duration of the trials varies, but many of them last for several months to over a year. For example, some pain management studies evaluate patients for up to 52 weeks, while others may have shorter or longer durations depending on the specific research objectives.

Ongoing Clinical Trials on Buclizine Hydrochloride

  • Evaluation of Safety and Efficacy of MK-2870 and Paclitaxel in Second-Line Treatment of Advanced/Metastatic Gastroesophageal Adenocarcinoma

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Italy Norway

  • Study of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Ireland Italy The Netherlands Poland +1

  • Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +7

  • Study of felzartamab compared to placebo in adults with IgA nephropathy

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia France Germany +5

  • Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +10

  • Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Czechia Denmark France Germany Greece +7

  • Study of Ifinatamab Deruxtecan and Pembrolizumab, With or Without Chemotherapy, for Patients With Untreated Advanced Esophageal Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Czechia France Germany Italy Norway

  • Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +8

  • Study Comparing Serratus Plane Block, Capsaicin, and Botulinum Toxin Type A for Chronic Pain in Post-Mastectomy Patients

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of Tregs and Rituximab for Children with Early Stage Type 1 Diabetes

    Recruiting

    2 1 1
    Investigated drugs:
    Poland

Glossary

  • Neuropathic Pain: Pain caused by damage or disease affecting the nervous system. It often feels like burning, stabbing, or shooting pain.
  • Lupus Nephritis: A kidney inflammation caused by systemic lupus erythematosus (SLE), an autoimmune disease.
  • Propionic Acidemia: A rare inherited disorder in which the body is unable to process certain parts of proteins and fats properly.
  • B-cell Lymphoma: A type of cancer that affects B lymphocytes, a kind of white blood cell that helps fight infections.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Quality of Life (QoL): A measure of an individual's well-being that includes physical, mental, and social aspects of life.
  • Numeric Rating Scale (NRS): A pain assessment tool where patients rate their pain intensity on a scale, typically from 0 (no pain) to 10 (worst pain imaginable).
  • Efficacy: The ability of a drug or medical treatment to produce a desired effect.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-ap707-gabapentin-and-capsaicin-for-patients-with-chronic-pain-from-traumatic-or-post-operative-peripheral-neuropathy/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ap707-with-lamotrigine-and-amitriptyline-for-patients-with-chronic-central-neuropathic-pain/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ap707-and-naproxen-for-patients-with-chronic-back-pain/
  4. http://clinicaltrials.eu/trial/study-on-the-safety-and-dosage-of-gd2il18cart-for-patients-with-relapsed-or-refractory-gd2-positive-solid-cancers/